Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.01.30
Imiquimod (IMQ)-induced psoriasis model
We are pleased to announce that starting today we are expanding our preclinical services and adding the “Imiquimod (IMQ)-induced dermatitis model“, a mouse model for psoriasis, to our lineup. Psoriasis is a refractory skin disease that is caused by both genetic and environmental factors. It causes chronic inflammation characterized by the clinical appearance of…
2025.01.30
Silica-induced pulmonary fibrosis model
We would like to introduce the “Silica-induced pulmonary fibrosis model“. Pulmonary fibrosis in silica models occurs early and is maintained long term. Hence, this model is one of the most beneficial model mice for therapeutic study for pulmonary fibrosis. In general, human pulmonary fibrosis does not resolve, whereas fibrosis in bleomycin model, a typical…
2025.01.30
Anti-Angiogenic Drug for HCC: STAM model
We would like to focus on Hepatocellular Carcinoma (HCC). Tumor angiogenesis plays a crucial role in supplying a tumor with oxygen and nutrients to sustain optimal growth. As HCC is a typical hypervascular tumor that forms a network of blood vessels, inhibiting tumor angiogenesis is expected to be useful in the treatment of HCC….
2025.01.30
Introduction to the hepatocellular carcinoma model (DEN-CCl4 model)
We would like to introduce the DEN-CCl4 mouse model for hepatocellular carcinoma (HCC). We focus on key pathophysiological events of human cirrhosis-associated hepatocarcinogenesis and have selected the DEN-CCl4 mouse model where chronic liver fibrosis leads to dramatic potentiation of the liver tumor incidence, with 100% of mice developing liver tumors at 30 weeks of…
2025.01.30
The relationship between liver disease and sarcopenia
Today, we would like to introduce the interaction between the liver and the muscular system. The liver has been known to work closely with other organs and in fact, in previous emails, we have mentioned some of the interactions between the liver and gut. However, today we would like focus on how the liver…
2025.01.30
The STAM mouse model: a clinically relevant, spontaneous HCC model
Today, we would like to introduce a study published by our client using our STAMTM mouse model (Dow, et al. Proc Natl Acad Sci U S A. 2018). The STAMTM model is a pathological model, with a NASH background, that spontaneously develops hepatocellular carcinoma (HCC). In this paper, the author compared the transcriptomes taken…
2025.01.30
Effect of the gut-liver axis dysfunction in liver disease
Today, We would like to introduce the relationship between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and the gut. MASLD is a disease that progresses from fatty liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH) to liver fibrosis and finally to liver cancer. As various factors such as diet and metabolic abnormalities are involved in the progression…
2025.01.30
Drug Efficacy Studies in NASH Mouse Model_ Mesenchymal stem/stromal cell small extracellular vesicles
Today’s topic is Effective cell therapy and exosome for NASH treatment. I would like to introduce a study published by our client, Agency for Science, Technology and Research (A*STAR) (SGP), in which they used our pre-clinical services in our proprietary NASH model called STAM™. Title: MSC-sEV Treatment Polarizes Pro-Fibrotic M2 Macrophages without Exacerbating Liver…
2025.01.30
Preventing Liver Cancer by Improving the Intestinal Dysbiosis
Today, we would like to introduce a study case of drug efficacy evaluation study using our mouse model of liver cancer caused by chronic liver disease (MASH/NASH). In this studies using our liver cancer model mice, it was found that not only the liver but also the intestines are important target organs in the treatment…
2025.01.30
Gut Microbiome As a Target For NASH Therapeutics Study
We introduce the development of drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) focusing on the gut microbiome and overview of studies using our STAMTM mice. Currently, the development of treatment and prevention methods for various diseases targeting the gut microbiome is progressing around the world. The relationship between MASH and the gut microbiome, such as…
We can help you advance your research.